Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
Portfolio Pulse from Benzinga Newsdesk
Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, announced that the European Medicines Agency (EMA) has granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome (GBS). The U.S. Food and Drug Administration (FDA) had previously granted the same designation to ANX005.
October 10, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The orphan drug designation granted by EMA to ANX005, a drug developed by Annexon, Inc., could potentially boost the company's stock in the short term.
The orphan drug designation is a significant regulatory milestone that can accelerate the development and approval process of a drug. This news could potentially increase investor confidence in Annexon, leading to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100